




The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 176% points. The greatest weakness of Monopar Therapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 390%, being 152% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	13,230
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	724
Liabilities, Non-Current	0
Other Assets	122
Other Compr. Net Income	-8.6
Other Expenses	0
Other Liabilities	0
Other Net Income	99
Other Revenues	0
Property and Equipment	0
Research and Development	1,969
Selling, General and Administrative Expense	2,355

Output Variable	Value in 1000 USD
Assets	13,352
Liabilities	724
Expenses	4,324
Revenues	0
Stockholders Equity	12,628
Net Income	-4,225
Comprehensive Net Income	-4,229
BaseVar	9,254
ECR before Limited Liability	331%
Economic Capital Ratio	390%